-
公开(公告)号：US06900197B2
公开(公告)日：2005-05-31
申请号：US10020867
申请日：2001-12-14
Applicant: Tomas R. Szabo , Soumitra S. Ghosh , Robert E. Davis
Inventor： Tomas R. Szabo , Soumitra S. Ghosh , Robert E. Davis
IPC: A61K31/409 , A61K33/24 , A61P3/04 , C07D487/22 , C07F15/06 , A61K31/555 , A61K31/40 , A61K31/415
CPC classification number: C07D487/22
Abstract: Cobalt-porphyrin (Co-P) complexes for use as anti-obesity agents, and compositions and methods related thereto. The Co-P complexes exhibit reduced redox activity compared to cobalt mesoporphyrin (Co-MP) and cobalt protoporphyrin (Co-PP), which alleviates the deleterious effects associated with administration of Co-P associated with oxidative stress, particularly in the context of injection site toxicity.
-
公开(公告)号：US06867197B1
公开(公告)日：2005-03-15
申请号：US09448312
申请日：1999-11-23
Applicant: Robert E. Davis , Soumitra S. Ghosh , John S. Kiely
Inventor： Robert E. Davis , Soumitra S. Ghosh , John S. Kiely
CPC classification number: C07D219/08 , A61K38/00 , A61K47/541 , A61K47/545 , C07K14/4711 , C07K14/4713 , C12N9/0053 , C12Q1/6806 , C12Q2527/101
Abstract: The present invention relates to genetic mutations in mitochondrial cytochrome c oxidase genes that segregate with Alzheimer's disease (AD). The invention provides methods for detecting such mutations, as a diagnostic for Alzheimer's Disease, either before or after the onset of clinical symptoms. The invention further provides treatment of cytochrome c oxidase dysfunction.
Abstract translation: 本发明涉及与阿尔茨海默氏病（AD）分离的线粒体细胞色素c氧化酶基因中的遗传突变。 本发明提供了在临床症状发作之前或之后检测这种突变作为阿尔茨海默病诊断的方法。 本发明进一步提供细胞色素c氧化酶功能障碍的治疗。
-
公开(公告)号：US06511966B2
公开(公告)日：2003-01-28
申请号：US09933911
申请日：2001-08-20
Applicant: Soumitra S. Ghosh , Scott W. Miller , Robert E. Davis , Walter H. Moos
Inventor： Soumitra S. Ghosh , Scott W. Miller , Robert E. Davis , Walter H. Moos
IPC: A01N4304
CPC classification number: A61K31/155 , A61K31/00 , A61K31/05 , A61K31/06 , A61K31/136 , C07C39/08 , C07C39/11 , C07C39/19 , C07C69/017 , C07C215/78 , C07C215/80 , C07C217/84 , C07C279/18 , C07D215/20 , C07D311/72
Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus. Parkinson's Disease, neuronal and cardiac ischemia. Huntington's disease and stroke.
-
公开(公告)号：US06489095B2
公开(公告)日：2002-12-03
申请号：US09098079
申请日：1998-06-15
Applicant: Corinna Herrnstadt , Soumitra S. Ghosh , William Clevenger , Eoin D. Fahy , Robert E. Davis
Inventor： Corinna Herrnstadt , Soumitra S. Ghosh , William Clevenger , Eoin D. Fahy , Robert E. Davis
IPC: C12Q168
CPC classification number: C12Q1/6883 , C12Q1/6827 , C12Q2600/156 , C12Q2600/172
Abstract: Compositions and methods based on quantification of extramitochondrial DNA (exmtDNA) sequences are provided that are useful for detecting the presence of or risk for having a disease associated with altered mitochondrial function, and for identifying agents suitable for treating such diseases. The exmtDNA sequences have strong homology to authentic mitochondrial DNA (mtDNA) sequences.
-
45.发明授权Compositions and methods for assaying subcellular conditions and processes using energy transfer 失效使用能量转移分析亚细胞条件和过程的组合物和方法公开(公告)号：US06280981B1
公开(公告)日：2001-08-28
申请号：US09514569
申请日：2000-02-23
Applicant: James A. Dykens , Gönül Veliçelebi , Soumitra S. Ghosh
Inventor： James A. Dykens , Gönül Veliçelebi , Soumitra S. Ghosh
IPC: C12P1314
CPC classification number: G01N33/582 , G01N33/5005 , G01N33/5079 , G01N33/542 , G01N2500/00
Abstract: The invention is provides compositions and methods for monitoring subcellular compartments such as organelles by energy transfer techniques that do not require specific intermolecular affinity binding events between energy transfer donor and energy transfer acceptor molecules. Provided are methods for assaying cellular membrane potential, including mitochondrial membrane potential, by energy transfer methodologies including fluorescence resonance energy transfer (FRET). Diagnostic and drug screening assays are also provided.
Abstract translation: 本发明提供了通过能量转移技术监测亚细胞隔室例如细胞器的组合物和方法，其不需要能量转移供体和能量转移受体分子之间的特异性分子间亲和力结合事件。 提供了通过能量转移方法（包括荧光共振能量转移（FRET））来测定细胞膜电位的方法，包括线粒体膜电位。 还提供诊断和药物筛选测定。
-
Patent Agency Ranking
46.发明申请公开(公告)号：US20180344813A1
公开(公告)日：2018-12-06
申请号：US15177397
申请日：2016-06-09
Applicant: Mary ERICKSON , David C. LITZINGER , Soumitra S. GHOSH , Zijian GUO , Manoj P. SAMANT , Abhinandini SHARMA , Lala MAMEDOVA , Odile Esther LEVY , Caroline EKBLAD
Inventor： Mary ERICKSON , David C. LITZINGER , Soumitra S. GHOSH , Zijian GUO , Manoj P. SAMANT , Abhinandini SHARMA , Lala MAMEDOVA , Odile Esther LEVY , Caroline EKBLAD
Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
-
47.发明授权Engineered polypeptides having enhanced duration of action with reduced immunogenicity 有权具有增强的作用持续时间并具有降低的免疫原性的工程化多肽公开(公告)号：US09382304B2
公开(公告)日：2016-07-05
申请号：US14129815
申请日：2012-07-03
Applicant: Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad
Inventor： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad
IPC: C07K14/605 , A61K47/48 , C12N15/62
CPC classification number: C07K14/605 , A61K47/65 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/70
Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
Abstract translation: 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括口服给药和降低的免疫原性。 所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。 还提供了治疗疾病和病症的药物组合物和方法，包括肥胖和超重，糖尿病，血脂异常，高脂血症，阿尔茨海默病，脂肪肝疾病，短肠综合症，帕金森病和心血管疾病。
-
公开(公告)号：US09217022B2
公开(公告)日：2015-12-22
申请号：US13812445
申请日：2011-07-27
Applicant: Josue Alfaro-Lopez , Abhinandini Sharma , Christopher J. Soares , Eugene Coats , Soumitra S. Ghosh
Inventor： Josue Alfaro-Lopez , Abhinandini Sharma , Christopher J. Soares , Eugene Coats , Soumitra S. Ghosh
IPC: C07K14/605 , A61K38/00
CPC classification number: C07K14/605 , A61K38/00 , Y02E50/343
Abstract: The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.
Abstract translation: 本公开提供了具有对应于天然肽化合物的α-螺旋区域的稳定区域的GLP-1受体激动剂化合物。 本公开还提供含有苯甲酰胺的毒蜥外泌肽-4类似物和烯烃受限的毒蜥外泌肽-4类似物，两者都具有对应于毒蜥外泌肽-4的α-螺旋区域的稳定区域。
-
49.发明申请ENGINEERED POYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY 审中-公开具有增强作用持续时间和降低免疫原性的工程应用公开(公告)号：US20140256621A1
公开(公告)日：2014-09-11
申请号：US14129793
申请日：2012-07-03
Applicant: Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Caroline Ekbland , Jonathan David Roth
Inventor： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Caroline Ekbland , Jonathan David Roth
IPC: C07K14/575 , C07K14/315
CPC classification number: C07K14/5759 , A61K38/00 , A61K38/22 , A61K38/2264 , C07K14/315 , C07K14/575 , C07K2319/31 , C07K2319/70
Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
Abstract translation: 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括每周给药一次。 所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。 还提供了包括脂肪营养不良，血脂异常，高脂血症，超重，肥胖，下丘脑闭经，阿尔茨海默病，瘦素缺乏症，脂肪肝疾病或糖尿病（包括I型和II型）的疾病和病症的药物组合物和治疗方法。 可以通过本文所述的化合物和方法治疗的其它疾病和病症包括非酒精性脂肪性肝炎（NASH）和非酒精性脂肪性肝病（NAFLD），代谢综合征X和亨廷顿氏病。
-
50.发明申请ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY 有权具有减少免疫原性的增强作用时间的工程多糖公开(公告)号：US20140235535A1
公开(公告)日：2014-08-21
申请号：US14129815
申请日：2012-07-03
Applicant: Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad
Inventor： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad
IPC: C07K14/605
CPC classification number: C07K14/605 , A61K47/65 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/70
Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
Abstract translation: 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括口服给药和降低的免疫原性。 所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。 还提供了治疗疾病和病症的药物组合物和方法，包括肥胖和超重，糖尿病，血脂异常，高脂血症，阿尔茨海默病，脂肪肝疾病，短肠综合症，帕金森病和心血管疾病。
-
-
-
-
-
-
-
-
-
Search Results
57
records
(took 0.031 seconds)
